Annexin Pharmaceuticals AB (OSTO:ANNX) General and Admin. Expense: kr11.07 Mil (TTM As of Mar. 2026)


OSTO:ANNX Annexin Pharmaceuticals AB OSTO:ANNX
23 GF Score
Price kr12.05
! 1 Warning Sign
View Full Analysis

What is Annexin Pharmaceuticals AB General and Admin. Expense?

Annexin Pharmaceuticals AB OSTO:ANNX 23 General and Admin. Expense is kr11.07 Mil as of Mar. 2026. GuruFocus rates OSTO:ANNX with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Annexin Pharmaceuticals AB's General and Admin. Expense for the three months ended in Mar. 2026 was kr2.90 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr11.07 Mil.

Annexin Pharmaceuticals AB General and Admin. Expense Related Terms

Annexin Pharmaceuticals AB General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for Annexin Pharmaceuticals AB's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Annexin Pharmaceuticals AB General and Admin. Expense Chart

Annexin Pharmaceuticals AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.70 12.29 8.01 9.59 10.07

Annexin Pharmaceuticals AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 3.57 2.35 2.26 2.90
OSTO:ANNX
23GF Score
Annexin Pharmaceuticals AB OSTO:ANNX
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Annexin Pharmaceuticals AB General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr11.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of kr11.07 Mil mean?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a General and Admin. Expense of kr11.07 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Annexin Pharmaceuticals AB and its competitors.
Is Annexin Pharmaceuticals AB's General and Admin. Expense too high?
Annexin Pharmaceuticals AB's current General and Admin. Expense is kr11.07 Mil. Overall, Annexin Pharmaceuticals AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Annexin Pharmaceuticals AB's General and Admin. Expense compare to VRTX and REGN?
Annexin Pharmaceuticals AB's General and Admin. Expense of kr11.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on Annexin Pharmaceuticals AB and its competitors. Annexin Pharmaceuticals AB's current General and Admin. Expense is kr11.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annexin Pharmaceuticals AB stock overvalued right now?
Annexin Pharmaceuticals AB (OSTO:ANNX) has a current General and Admin. Expense of kr11.07 Mil. The current General and Admin. Expense is kr11.07 Mil. Annexin Pharmaceuticals AB's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For Annexin Pharmaceuticals AB (OSTO:ANNX), the current General and Admin. Expense is kr11.07 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Annexin Pharmaceuticals AB Business Description

Other Exchanges Q910:Germany
Address Kammakargatan 48, Stockholm, SWE, 111 60
Annexin Pharmaceuticals AB is a biotechnology company. It is developing biological drug candidate ANXV, a recombinant human protein Annexin A5 for treatment of various cardiovascular diseases. The company also focuses on development of ANXV for the treatment of retinal vein occlusion.
23GF Score

Get the complete analysis for OSTO:ANNX

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr12.05
Price